U.S. markets open in 2 hours 50 minutes

Verastem, Inc. (VSTM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3500-0.0100 (-0.42%)
At close: 4:00PM EST

2.3800 +0.03 (1.28%)
Pre-Market: 6:35AM EST

Verastem, Inc.

117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
http://www.verastem.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees135

Key Executives

NameTitlePayExercisedYear Born
Mr. Brian Stuglik R.Ph., RPhCEO & Director890.32kN/A1959
Mr. Daniel W. PatersonCOO & Pres679.82kN/A1961
Mr. Robert E. GagnonCFO & Chief Bus. Officer586.64kN/A1974
Mr. Richard H. Aldrich M.B.A., MbaFounder and ConsultantN/AN/A1954
Dr. Robert A. Weinbergnder & Former Chair of Scientific Advisory BoardN/AN/AN/A
Dr. Piyush B. Gupta Ph.D.Co-FounderN/AN/AN/A
Dr. Michelle DippCo-FounderN/AN/A1976
Dr. Jonathan Pachter Ph.D.Chief Scientific OfficerN/AN/A1958
Ms. Erin S. CoxSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Sean C. FlynnVP, Gen. Counsel & Sec.N/AN/A1974
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.

Corporate Governance

Verastem, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.